# Terasaki生物醫學創新研究所與亞利桑那大學醫學院的研究人員開發出含4-氨基吡啶（4-AP）的局部凝膠配方，用於治療燒傷。

*biotech · news · 2026-06-04 · Medical Xpress*

## Key points

- 含4-氨基吡啶的局部膠體-明膠凝膠在48小時內實現超過90%的燒傷傷口閉合。
- 透過凝膠局部給藥4-AP，避免口服使用時出現的嚴重全身副作用。
- 動物實驗顯示，治療組傷口在第21天幾乎完全閉合，相較對照組明顯改善。
- 治療組傷口的第一型膠原蛋白沉積量增加438%，第三型膠原蛋白增加288%。
- 重新利用FDA核准的4-AP可加速燒傷治療的臨床試驗進程。

Researchers at the Terasaki Institute for Biomedical Innovation and the University of Arizona College of Medicine have developed a topical gel formulation with 4-aminopyridine (4-AP), to treat burn wounds, achieving near-complete closure in 21 days. The findings are published in the journal Biomaterials. Burn injuries rank among the most difficult wounds to heal. The current gold standard, transplanting skin from a donor site on the patient's own body, is limited by donor site morbidity and the need for large amounts of healthy tissue. This research offers a noninvasive alternative: a laponite-gelatin gel that delivers 4-AP directly to the wound, concentrating the drug where it is needed rather than exposing the whole body to it. Prolonged systemic use of 4-AP can cause serious side effects, including seizures, making localized delivery a critical advance. The drug is best known for treating multiple sclerosis under the brand name Ampyra. Earlier work showed it could influence keratinocytes and fibroblasts, the two cell types central to skin repair, but systemic administration carried unacceptable risks. Embedding it in a gel resolves that problem while preserving its therapeutic potential. "By delivering 4-AP directly to the wound site, we harness its regenerative potential while avoiding the systemic risks that have limited its use. We believe this approach could meaningfully change how burn injuries are managed clinically," said Dr. Johnson V. John, Assistant Professor at the Terasaki Institute for Biomedical Innovation. Laboratory tests confirmed that the gel releases 4-AP at a controlled rate, is compatible with living cells, and produces more than 90% wound closure within 48 hours. In animal studies, treated wounds closed faster than controls starting at day six, reaching near-complete closure by day 21, while control wounds remained partially open. Tissue analysis showed the gel reduced inflammation, promoted re-epithelialization and angiogenesis, and drove fibroblast-to-myofibroblast transformation. Collagen deposition increased markedly by 438% for type I and 288% for type III versus controls (P < 0.05 to P < 0.0002), with an improved collagen ratio signaling better-quality tissue maturation. Because 4-AP is already FDA-approved with a well-characterized safety profile, this repurposing strategy could accelerate the path to clinical trials compared with developing an entirely new compound from scratch. "This research exemplifies our commitment to reimagining existing therapies to address medicine's most persistent challenges. We look forward to seeing it advance toward clinical application," stated Xiling Shen, Acting Director of the Terasaki Institute for Biomedical Innovation. This study represents a meaningful step forward in burn wound care, demonstrating that a well-established drug can be safely repurposed through simple and smart delivery technology to achieve outcomes that current treatments cannot. As the researchers move toward further preclinical and clinical evaluation, the 4-AP gel has the potential to offer burn patients a faster, less invasive path to recovery and to reduce the burden that severe burn injuries place on patients and health care systems alike. Provided by Terasaki Institute for Biomedical Innovation

[Read the full story on Medical Xpress](https://medicalxpress.com/news/2026-06-topical-gel-wounds-faster-fda.html)

---

Canonical: https://newsio.io/zh-TW/n/06461405-1ff3-46cf-bade-16f5b9b5c6e9/terasaki4-4-ap
Summarized by Newsio from Medical Xpress. https://newsio.io/how-it-works